Toes-Zoutendijk E. Interval cancers after a negative faecal immunochemical test in the first screening round in the Netherlands: results for two cut-off levels. UEG Week 2018, LB14.
Camrelizumab plus rivoceranib versus sorafenib als eerstelijnsbehandeling bij inoperabel HCC
nov 2023 | Hepatologie, Immuuntherapie, Maag-darm-leveroncologie